Intrapericardial Triamcinolone Instillation for Recurrent Pericardial Effusion in Pediatric Patients: A Review of Efficacy and Safety - Report - MDSpire
Advertisement
Intrapericardial Triamcinolone Instillation for Recurrent Pericardial Effusion in Pediatric Patients: A Review of Efficacy and Safety
Clinical Report: Efficacy and Safety of Intrapericardial Triamcinolone Injection
Overview
This report reviews the efficacy and safety of intrapericardial triamcinolone injection for treating recurrent pericardial effusion in children based on a retrospective case series.
Background
Recurrent pericardial effusion in children is a significant clinical challenge, often requiring repeated interventions. Current treatment options include systemic corticosteroids, which can lead to adverse effects, and intrapericardial triamcinolone has emerged as an alternative.
Data Highlights
This report is based on a retrospective case series conducted from 2015 to 2025, involving children who received intrapericardial triamcinolone for recurrent pericardial effusion.
Key Findings
Intrapericardial triamcinolone was administered at a dose of 300 mg/m2 during pericardiocentesis.
Patients were monitored for recurrence of pericardial effusion post-treatment.
Adverse events, including adrenal insufficiency, were noted in some patients.
The study included children under 18 years with a history of recurrent pericardial effusion.
Follow-up data were collected retrospectively to assess treatment outcomes.
Clinical Implications
Clinicians should be vigilant about potential systemic adverse effects associated with intrapericardial triamcinolone.
Conclusion
Intrapericardial triamcinolone injection is evaluated for recurrent pericardial effusion in children.
